Why small pharma struggles with pharmacovigilance

Most early-stage biotechs reach IND or first-in-human studies without a documented pharmacovigilance system in place. Regulators — FDA, EMA, and country-level competent authorities — require a functioning PV system before or at the start of clinical trials. Without one, you risk clinical hold, delayed approvals, or a failed inspection.

Nimble PV establishes your PV system from scratch: PSMF, SOPs, signal detection log, expedited reporting procedures, and a named QPPV — all built to your asset stage and market footprint.

The EU requires a Qualified Person for Pharmacovigilance (QPPV) with EU residency for any MA holder or clinical trial sponsor operating in Europe. Finding one who will accept accountability for a single asset — without a full-time contract — is nearly impossible through traditional hiring.

Nimble PV provides a named, EU-resident Fractional QPPV who takes formal regulatory accountability for your PV system. Same legal standing as a full-time hire, at a fraction of the cost.

CROs provide trial-level safety oversight — they manage SAE reporting within the study, but they don't build or own your company-level PV system. When the trial ends or your CRO relationship changes, the institutional knowledge walks out the door. Most CROs also use templated SOPs that don't reflect your specific regulatory markets or asset profile.

Nimble PV operates as your company-side PV function, independent of any CRO. We review and challenge CRO safety deliverables, ensure they feed into your PSMF correctly, and maintain continuity across partners and trials.

Expedited safety reporting has hard deadlines: 7 days for fatal or life-threatening SUSARs, 15 days for all other serious unexpected reactions, 24 hours for certain IND safety reports. Missing a deadline triggers regulatory scrutiny. At small biotechs, SAE intake often lands on a medical monitor or CMO already stretched across multiple roles.

Nimble PV takes 24/7 SAE intake responsibility, handles medical review and causality assessment, and submits ICSRs to EudraVigilance, FAERS, and local authorities within required timelines. You get notified — you don't have to manage the clock.

Regulatory inspections — GCP inspections, PV inspections, triggered audits — arrive with 6–8 weeks notice. At that point, assembling consultants and writing SOPs from scratch is too late. Inspectors look for evidence of a functioning system over time: signal reviews, audit trails, training records, PSMF versioning.

Nimble PV builds inspection-ready PV systems from day one. Signal detection meetings are documented. The PSMF is versioned. Training records are current. When an inspection notice arrives, we mobilise within 24 hours and lead the preparation.

A VP of Pharmacovigilance with the credentials to handle FDA and EMA oversight costs $300–400K in total compensation — before benefits, equity, and overhead. For a company with one Phase 1 asset and 18 months of runway, that's a hire you can't justify. But the regulatory requirement doesn't go away because you're early-stage.

Nimble PV's fractional model gives you VP-level expertise and formal regulatory accountability for a fraction of full-time cost. The engagement scales with your program — you pay for what you need, when you need it.

Periodic safety reports have fixed regulatory submission deadlines tied to the international birth date of your product or your data lock date. Missing a PSUR, PBRER, or DSUR submission triggers non-compliance findings and can jeopardise your MA or clinical trial authorisation. Preparing them requires synthesis of all cumulative safety data — a significant analytical burden.

Nimble PV manages your aggregate report calendar, runs the data cut, prepares the safety narrative, and submits on time. We've written PSURs and PBRERs for assets across oncology, rare disease, and neurology — and can work with your clinical data management team on the line listings.

GVP Module IX requires a proactive signal detection process — not just a policy document. Regulators expect evidence of structured data review, disproportionality analysis where appropriate, and a documented signal log with outcomes. Most small biotechs have a signal detection SOP but no recurring process behind it.

Nimble PV runs quarterly signal detection reviews using your ICSR data, FAERS/EudraVigilance literature, and published spontaneous reports. Signals are logged, evaluated, and escalated per your risk management plan — with written outputs suitable for regulatory review.